Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Envestnet Inc.

    NYSE: ENV · Real-Time Price · USD
    63.14
    null (null%)
    At close: Nov 22, 2024, 9:00 PM
    undefined%
    Bid n/a
    Market Cap 3.49B
    Revenue (ttm) 1.33B
    Net Income (ttm) -261.52M
    EPS (ttm) -4.78
    PE Ratio (ttm) -13.209205020920502
    Forward PE n/a
    Analyst Hold
    Ask n/a
    Volume 0
    Avg. Volume (20D) 0
    Open undefined
    Previous Close undefined
    Day's Range 63.14 - 63.14
    52-Week Range 63.14 - 63.14
    Beta 1.25

    About ENV

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ENV
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ENV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 year ago
    Envestnet shares are trading higher following a re... Unlock content with Pro Subscription
    news image

    1 month ago · businesswire.com

    Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

    LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib af...

    news image

    1 month ago · businesswire.com

    Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

    LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the “Company'”), announces the completion of the safety lead-in of its Phase 2 clin...

    news image

    2 months ago · businesswire.com

    NewEdge Investment Solutions Now Available on Envestnet, SMArtX Platforms

    STAMFORD, Conn.--(BUSINESS WIRE)--NewEdge Wealth, LLC, a registered investment advisor specializing in serving ultra high net worth families, family offices and institutional clients, announced today ...

    news image

    3 months ago · businesswire.com

    Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

    LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, C...

    Add to Watchlist